Purchase this article with an account.
L. J. Wong, R. U. Desai, A. Jain, D. Feliciano, D. M. Moshfeghi, S. R. Sanislo, M. S. Blumenkranz; Potential Adverse Events Associated With Intravitreal Bevacizumab for Retinal and Choroidal Vascular Disease. Invest. Ophthalmol. Vis. Sci. 2008;49(13):254.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To systematically study potential adverse events associatedwith the use of intraocular bevacizumab at a single medicalcenter.
Retrospective study of all consecutive patients receiving intraocularbevacizumab injections at the Stanford University Departmentof Ophthalmology between November 15, 2005 and July 14, 2006.Bevacizumab was given for exudative age-related macular degeneration(AMD), retinal vascular occlusion, diabetic macular edema (DME),neovascular glaucoma (NVG), myopic choroidal neovascularization(CNV), von Hippel-Lindau (vHL) disease, and CNV that was idiopathic,trauma-induced, or vasculitis-related.
We analyzed medical records of 188 subjects (205 eyes) who receiveda total of 578 injections of 1.25 mg bevacizumab. Follow-uprate was 97%. The average follow-up was approximately 6 months.5 eyes with exudative AMD developed retinal pigment epithelial(RPE) tears, all with pre-existing RPE detachments (RPED’s).These 5 eyes represented 3% of all eyes treated and 7% of theeyes with pre-existing RPED’s at initiation of treatment.No subject experienced thromboembolic complications or death.Other adverse events were rare. Eyes treated for AMD gainedabout 1 line Snellen of visual acuity (p < 0.05).
Intraocular bevacizumab appears to be well-tolerated for thetreatment of a variety of retinal and choroidal vascular diseases.RPE tears may occur when treating choroidal neovascularization,particularly in patients with pre-existing RPE detachment.
This PDF is available to Subscribers Only